Purpose. Extracellular protein toxins contribute to the pathogenesis of Staphylococcus aureus infections. The present study compared the effects of iclaprim and trimethoprim – two folic acid synthesis inhibitors – with nafcillin and vancomycin on production of Panton–Valentine leukocidin (PVL), alpha haemolysin (AH) and toxic-shock syndrome toxin I (TSST-1) in methicillin-resistant and vancomycin-intermediate S. aureus (MRSA and VISA, respectively).
Methodology. Northern blotting and RT-PCR were used to assess gene transcription; toxin-specific bioassays were used to measure protein toxin production.
Results. As shown previously, sub-inhibitory concentrations (sub-MIC) of nafcillin increased and prolonged MRSA toxin gene transcription and enhanced PVL, TSST-1 and AH production. Sub-inhibitory doses of iclaprim and trimethoprim delayed maximal AH gene (hla) transcription and suppressed AH production; both drugs delayed, but neither reduced, maximal TSST-1 production. Trimethoprim significantly increased lukF-PV expression and PVL production compared to both untreated and iclaprim-treated cultures. Higher concentrations of iclaprim and trimethoprim markedly suppressed MRSA growth, mRNA synthesis and toxin production. In VISA, iclaprim, vancomycin and nafcillin variably increased tst and hla expression, but only nafcillin increased toxin production. Despite its ability to increase hla expression, iclaprim was the most potent inhibitor of AH production.
Conclusions. We conclude that, due to its ability to suppress toxin production, iclaprim should be effective against severe staphylococcal infections caused by toxin-producing MRSA and VISA strains, especially given its ability to concentrate at sites of infection such as skin and skin structures and the lung.
EntenzaJM, HaldimannA, GiddeyM, LociuroS, HawserS et al. Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model. Antimicrob Agents Chemother2009; 53:3635–3641 [View Article]
StevensDL, MaY, SalmiDB, McIndooE, WallaceRJ et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis2007; 195:202–211 [View Article]
HamiltonSM, BryantAE, CarrollKC, LockaryV, MaY et al.In vitro production of Panton-Valentine Leukocidin (PVL) among strains of methicillin-resistant Staphylococcus aureus causing diverse infections. Clin Infect Dis2007; 45:1550–1558
LiZ, StevensDL, HamiltonSM, ParimonT, MaY et al. Fatal S. aureus hemorrhagic pneumonia: genetic analysis of a unique clinical isolate producing both PVL and TSST-1. PLoS One2011; 6:e27246 [View Article]
DiepBA, SensabaughGF, SomboonaNS, CarletonHA, Perdreau-RemingtonF. Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J Clin Microbiol2004; 42:2080–2084 [View Article]
BabaT, TakeuchiF, KurodaM, YuzawaH, AokiK et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet2002; 359:1819–1827 [View Article]
SakoulasG, EliopoulosGM, MoelleringRC, WennerstenC, VenkataramanL et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother2002; 46:1492–1502 [View Article]
National Committee for Clinical Laboratory StandardsMethods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, NCCLS Approved standard. 2003M7–06
GemmellCG, PetersonPK, SchmelingDJ, QuiePG. Effect of staphylococcal alpha-toxin on phagocytosis of staphylococci by human polymorphonuclear leukocytes. Infect Immun1982; 38:975–980
KernodleDS, McGrawPA, BargNL, MenziesBE, VoladriRK et al. Growth of Staphylococcus aureus with nafcillin in vitro induces alpha-toxin production and increases the lethal activity of sterile broth filtrates in a murine model. J Infect Dis1995; 172:410–419 [View Article]
van LangeveldeP, van DisselJT, MeursCJ, RenzJ, GroeneveldPH. Combination of flucloxacillin and gentamicin inhibits toxic shock syndrome toxin 1 production by Staphylococcus aureus in both logarithmic and stationary phases of growth. Antimicrob Agents Chemother1997; 41:1682–1685 [View Article]
LivakKJ, SchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods2001; 25:402–408 [View Article]
StevensDL, VanS, BryantAE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis1993; 167:1401–1405 [View Article]
AldapeMJ, PackhamAE, NuteDW, BryantAE, StevensDL. Effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile. J Med Microbiol2013; 62:741–747 [View Article]
StevensDL, MaierKA, MittenJE. Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob Agents Chemother1987; 31:213–218 [View Article]
StevensDL, BisnoAL, ChambersHF, DellingerEP, GoldsteinEJ et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases Society of America. Clin Infect Dis2014; 59:e10–e52
OefnerC, BanderaM, HaldimannA, LaueH, SchulzH et al. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. J Antimicrob Chemother2009; 63:687–698 [View Article]
HollandTL, O'RiordanW, McManusA, ShinE, BorgheiA et al. A phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous Iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens (REVIVE-2 study). Antimicrob Agents Chemother2018; 62:e02580–17 [View Article]
HuangDB, O'RiordanW, OvercashJS, HellerB, AminF et al. A phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim vs vancomycin for the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens: REVIVE-1. Clin Infect Dis2018; 66:1222–1229 [View Article]
RohlmanCE, MatthewsRG. Role of purine biosynthetic intermediates in response to folate stress in Escherichia coli. J Bacteriol1990; 172:7200–7210 [View Article]
BabitzkeP, GollnickP. Posttranscription initiation control of tryptophan metabolism in Bacillus subtilis by the trp RNA-binding attenuation protein (TRAP), anti-TRAP, and RNA structure. J Bacteriol2001; 183:5795–5802 [View Article]
HuangDB, FileTM, DrydenM, CoreyGR, TorresA et al. Surveillance of iclaprim activity: in vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe. Diagn Microbiol Infect Dis2018; 90:329–334 [View Article]
HuangDB, HawserS, GemmellCG, SahmDF. In vitro activity of Iclaprim against methicillin-resistant Staphylococcus aureus nonsusceptible to daptomycin, linezolid, or vancomycin: a pilot study. Can J Infect Dis Med Microbiol2017epub 2017 Dec 17 [View Article]